WAY-162720

WAY-162720

WAY-162720 is a synthetic compound that acts as a selective antagonist of the cannabinoid receptor type 1 (CB1). It was developed for research purposes to better understand the role of CB1 receptors in various physiological and pathological processes.

Chemical Structure and Properties

WAY-162720 is a small molecule with a complex chemical structure designed to specifically bind to the CB1 receptor, thereby inhibiting its activity. The molecular formula of WAY-162720 is C23H21N3O2, and it has a molecular weight of 371.43 g/mol. The compound is characterized by its high affinity for the CB1 receptor, with minimal activity at the cannabinoid receptor type 2 (CB2).

Mechanism of Action

WAY-162720 functions as a competitive antagonist at the CB1 receptor. By binding to the receptor, it prevents the endogenous ligands, such as anandamide and 2-arachidonoylglycerol, from activating the receptor. This blockade of CB1 receptor activity can modulate various physiological processes, including appetite regulation, pain sensation, mood, and memory.

Pharmacological Effects

The pharmacological effects of WAY-162720 have been studied in various animal models. As a CB1 antagonist, it has been shown to:

• Reduce food intake and body weight in animal models, suggesting potential applications in the treatment of obesity.
• Modulate pain perception, indicating possible use in pain management.
• Influence mood and anxiety, which could have implications for psychiatric disorders.

Research Applications

WAY-162720 is primarily used in research settings to explore the role of CB1 receptors in different biological systems. It helps in elucidating the physiological and pathological roles of the endocannabinoid system. Studies using WAY-162720 have contributed to understanding:

• The regulation of appetite and energy balance.
• The mechanisms underlying addiction and substance abuse.
• The modulation of pain and inflammation.

Safety and Toxicology

As a research compound, the safety and toxicology profile of WAY-162720 in humans is not well-established. In animal studies, it has been generally well-tolerated, but comprehensive toxicological evaluations are necessary before considering any potential therapeutic applications.

Also see

• Cannabinoid receptor type 1
• Endocannabinoid system
• CB1 receptor antagonists
• Anandamide
• 2-Arachidonoylglycerol